MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.43

-0.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/14/2007 5:23:27 PM
	of 2240

Genmab Initiates Ofatumumab Front Line NHL Study Thursday June 14, 5:01 pm ET Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Combination With CHOP as Front Line Treatment of Follicular NHL. COPENHAGEN, Denmark, June 14 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN - News) announced today it has initiated a Phase II study of ofatumumab (HuMax-CD20®) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). A total of 56 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline. "We are pleased to begin this study of ofatumumab for front line treatment offollicular NHL," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab, "which we hope may be more effective than currently available treatment." About the trial Patients in this open label study will be randomized into two dose groups of 28patients each and will receive 6 infusions of ofatumumab in combination with CHOP. Each patient will receive 300 mg of ofatumumab at the first infusion, followed by 5 subsequent infusions of either 500 or 1000 mg of ofatumumab every3 weeks, in combination with 6 cycles of CHOP. Disease status will be assessedat three months following the last treatment and then every three months until month 24, and every 6 months thereafter until 60 months or initiation of alternative treatment. The objective of the study is to determine the efficacy of two dose regimens of ofatumumab in combination with CHOP in previously untreated follicular NHL patients. The primary endpoint in the study is objective response from start of treatment until 3 months after last treatment assessed according to the standardized response criteria for NHL at 30 weeks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next